Company intelligence / Profile preview

Actin Biomed

South Brunswick Township, New Jersey, United Statesir.tgtherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Actinobac Biomed develops therapeutics based on its proprietary Leukothera platform. The lead candidates are designed to selectively target and eliminate disease-causing white blood cells for indications such as leukemia/lymphoma, dry eye disease, psoriasis, and HIV. The company remains private with ongoing research and development activities; no late-stage or commercialized products are reported as of now.

Therapeutic areas: DermatologyOphthalmologyOncologyInfectious Diseases
Modalities: ProteinBiologic
Industry: Biotech

Beyond the preview

Go deeper on Actin Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actin Biomed.

Explore the full profile